XML 98 R85.htm IDEA: XBRL DOCUMENT v3.25.0.1
Segment Reporting - Summary of Significant Expense Categories and Consolidated Net Loss (Details) - USD ($)
$ in Thousands
 12 Months Ended 154 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2024
Segment Reporting Information [Line Items]      
Revenue $ 98,427 $ 90,122  
Operating costs and expenses:      
Cost of goods sold 30,686 33,768  
Clinical development, contract manufacturing and other third party costs 76,850 57,249  
Employee costs 40,204 55,572  
Facilities costs 16,821 20,832  
Other operating costs 42,047 37,048  
Other segment expenses 37,407 149,337  
Gain on sale of the Huntsville manufacturing facility (40,390)    
Total operating costs and expenses 203,625 353,806  
Loss from operations (105,198) (263,684)  
Non-operating income (expense):      
Non-cash interest expense on liabilities related to the sales of future royalties (28,112) (25,334) $ (326,630)
Interest income 14,500 19,009  
Other income (expense), net (390) (6,247)  
Total non-operating income (expense), net (14,002) (12,572)  
Loss before provision for income taxes (119,200) (276,256)  
Rezpegaldesleukin (cytokine Treg stimulant)      
Operating costs and expenses:      
Clinical development, contract manufacturing and other third party costs 49,382 14,554  
NKTR-255 (IL-15 receptor agonist)      
Operating costs and expenses:      
Clinical development, contract manufacturing and other third party costs 15,795 26,132  
NKTR-0165 (tumor necrosis factor receptor type II agonist)      
Operating costs and expenses:      
Clinical development, contract manufacturing and other third party costs 9,339 9,345  
Discovery Research and Other Programs      
Operating costs and expenses:      
Clinical development, contract manufacturing and other third party costs $ 2,334 $ 7,218